EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Costs attributable to hypercholesterolemia in a single period and over the life cycle

Stephanie Reitzinger, Miriam Reiss, Thomas Czypionka

The European Journal of Health Economics · 2024

DOI: 10.1007/s10198-024-01684-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The European Journal of Health Economics, 2024. Verfasst von Stephanie Reitzinger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Advanced Studies, Josefstädter Str. 39, 1080, Vienna, Austria. reitzinger@ihs.ac.at. Hauptthemen laut MEDLINE: Hypercholesterolemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma GmbH Austria, Institute for Advanced Studies Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease leading to reduced (healthy) life years. The aim of this study is to quantify the societal costs associated with hypercholesterolemia. We use epidemiologic data on the distribution of cholesterol levels as well as data on relative risks regarding ischemic heart disease, stroke, and other cardiovascular diseases. The analytical approach is based on the use of population-attributable fractions applied to direct medical, direct non-medical and indirect costs using data of Austria. Within a life-cycle analysis we sum up the costs of hypercholesterolemia for the population of 2019 and, thus, consider future morbidity and mortality effects on this population. Epidemiologic data suggest that approximately half of Austria’s population have low-density lipoprotein cholesterol (LDL-C) levels above the target levels (i.e., are exposed to increased risk). We estimate that 8.2% of deaths are attributable to hypercholesterolemia. Total costs amount to about 0.33% of GDP in the single-period view. In the life-cycle perspective, total costs amount to €806.06 million, €312.1 million of which are medical costs, and about €494 million arise due to production loss associated with hypercholesterolemia. The study points out that significant shares of deaths, entries into disability pension and care allowance, full-time equivalents lost to the labor market as well as monetary costs for the health system and the society could be avoided if LDL-C-levels of the population were reduced.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercholesterolemiaHumansMaleFemaleMiddle AgedAgedAdultAustriaCost of IllnessCardiovascular DiseasesCholesterol, LDLRisk FactorsHealth Care CostsAged, 80 and overYoung Adult

Stichwörter der Autor:innen

AustriaCardiovascular diseasesHypercholesterolemiaLifecycleMacrolevel dataSocietal costs

Substanzen

Cholesterol, LDL

Autor:innen und Institutionen

  • Institute for Advanced Studies, Josefstädter Str. 39, 1080, Vienna, Austria. reitzinger@ihs.ac.at.
  • Institute for Advanced Studies, Josefstädter Str. 39, 1080, Vienna, Austria.
  • London School of Economics and Political Science, London, UK.

Förderung

  • Novartis Pharma GmbH Austria
  • Institute for Advanced Studies Vienna

Zitieren

APA

Reitzinger, S., Reiss, M., & Czypionka, T. (2024). Costs attributable to hypercholesterolemia in a single period and over the life cycle. The European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01684-0

Vancouver

Reitzinger S, Reiss M, Czypionka T. Costs attributable to hypercholesterolemia in a single period and over the life cycle. The European Journal of Health Economics. 2024. doi:10.1007/s10198-024-01684-0

BibTeX
@article{Reitzinger2024,
  author = {Reitzinger, Stephanie and Reiss, Miriam and Czypionka, Thomas},
  title = {Costs attributable to hypercholesterolemia in a single period and over the life cycle},
  journal = {The European Journal of Health Economics},
  year = {2024},
  doi = {10.1007/s10198-024-01684-0}
}
Kostenlos starten →